Source-grounded facts extracted from Jasper Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Christian Nolet resigned as Director at Jasper Therapeutics, Inc..
“On May 15, 2026 (the “Notice Date”), Christian Nolet informed the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) that he is resigning from the Board and the committees of the Board on which he serves, effective as of the Notice Date.”
Jasper Therapeutics, Inc. reported the quarter and year ended December 31, 2025 results: net income a net loss of $9.1 million and $75.8 million, or basic and diluted net loss per share attributable to common stockholder, EPS $0.32 and $3.95.
“Jasper reported a net loss of $9.1 million and $75.8 million, or basic and diluted net loss per share attributable to common stockholders of $0.32 and $3.95, for the three months and year ended December 31, 2025, respectively.”
Jasper Therapeutics, Inc. announced a restructuring with charges of approximately $1.8 million - $2.2 million affecting the Company (approximately 50%).
“in chronic urticaria and is halting other clinical and preclinical programs along with the reduction in workforce. The Company estimates that it will incur approximately $1.8 million - $2.2 million of cash expenditures in connection with the corporate reorganization, which relate to severance pay, and are expected to be incurred through the quarter ending”
Svetlana Lucas was appointed as Class III Director at Jasper Therapeutics, Inc..
“Effective immediately following Dr. French’s resignation, on June 18, 2024, the Board appointed Svetlana Lucas, Ph.D. as a Class III director of the Company.”
Anna French resigned as Director at Jasper Therapeutics, Inc..
“On June 17, 2024, Anna French, D.Phil. notified the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) of her intent to resign from the Board effective as of June 18, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.